The Aquaporin-3-Inhibiting Potential of Polyoxotungstates

• Main Authors: Catarina Pimpão, Inês V. da Silva, Andreia F. Mósca, Jacinta O. Pinho, Maria Manuela Gaspar, Nadiia I. Gumerova, Annette Rompel, Manuel Aureliano, Graça Soveral
• Format: Article
• Language: English
• Published: MDPI AG 2020-04-01
• Series: International Journal of Molecular Sciences
• Subjects: aquaporin; aquaglyceroporin; glycerol; polyoxotungstates; inhibitors; cancer
• Online Access: https://www.mdpi.com/1422-0067/21/7/2467
• ISSN: 1661-6596; 1422-0067

Polyoxometalates (POMs) are of increasing interest due to their proven anticancer activities. Aquaporins (AQPs) were found to be overexpressed in tumors bringing particular attention to their inhibitors as anticancer drugs. Herein, we report for the first time the ability of polyoxotungstates (POTs), such as of Wells–Dawson P₂W₁₈, P₂W₁₂, and P₂W₁₅, and Preyssler P₅W₃₀ structures, to affect aquaporin-3 (AQP3) activity and impair melanoma cell migration. The tested POTs were revealed to inhibit AQP3 function with different effects, with P₂W₁₈, P₂W₁₂, and P₅W₃₀ being the most potent (50% inhibitory concentration (IC₅₀) = 0.8, 2.8, and 3.2 µM), and P₂W₁₅ being the weakest (IC50 > 100 µM). The selectivity of P₂W₁₈ toward AQP3 was confirmed in yeast cells transformed with human aquaglyceroporins. The effect of P₂W₁₂ and P₂W₁₈ on melanoma cells that highly express AQP3 revealed an impairment of cell migration between 55% and 65% after 24 h, indicating that the anticancer properties of these compounds may in part be due to the blockage of AQP3-mediated permeability. Altogether, our data revealed that P₂W₁₈ strongly affects AQP3 activity and cancer cell growth, unveiling its potential as an anticancer drug against tumors where AQP3 is highly expressed.